Ann: Chairman and CEO's Addresses to Shareholders, page-4

noticed that narrative has changed now - it used to be nuvaring nuvaring...

this will fade into the abyss i think as they haven't even addressed the additional FDA requirements and once that has been submitted, this will take at least half a year for an action date. by then it will be an irrelevant product as the first to launch has gained traction and there might be more generic similar products already approved.

same narrative though in their excuses of getting lower sales due to competition. ALTHOUGH i note that specialty division which was once touted as the future of the firm is already facing problems in competitive products.

scott should go... even charts can probably do a better job than scott!